Advisory Commission on Childhood Vaccines Meeting, 77852-77853 [2022-27543]

Download as PDF 77852 Federal Register / Vol. 87, No. 243 / Tuesday, December 20, 2022 / Notices will occur in a federal government building and attendees must go through a security check to enter the building. Non-U.S. citizen attendees must notify HRSA of their planned attendance at least 20 business days prior to the meeting in order to facilitate their entry into the building. All attendees are required to present government-issued identification prior to entry. Maria G. Button, Director, Executive Secretariat. [FR Doc. 2022–27530 Filed 12–19–22; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Meeting of the Advisory Committee on Training and Primary Care Medicine and Dentistry Health Resources and Services Administration (HRSA), Department of Health and Human Services. ACTION: Notice. AGENCY: In accordance with the Federal Advisory Committee Act, this notice announces that the Advisory Committee on Training and Primary Care Medicine and Dentistry (ACTPCMD) will hold public meetings for the 2023 calendar year (CY). Information about ACTPCMD, agendas, and materials for these meetings can be found on the ACTPCMD website at https://www.hrsa.gov/advisorycommittees/primarycare-dentist. DATES: ACTPCMD meetings will be held on: • February 23, 2023, 10:00 a.m.–5:00 p.m. Eastern Time (ET) and February 24, 2023, 10:00 a.m.–4:00 p.m. ET; and • August 17, 2023, 10:00 a.m.–5:00 p.m. ET. ADDRESSES: Meetings will be held virtually and by teleconference. No inperson meetings will be conducted in 2023. For updates on how the meeting will be held, visit the ACTPCMD website 30 business days before the date of the meeting, where instructions for joining meetings will be posted. For meeting information updates, go to the ACTPCMD website meeting page at https://www.hrsa.gov/advisorycommittees/primarycare-dentist/ meetings. lotter on DSK11XQN23PROD with NOTICES1 SUMMARY: FOR FURTHER INFORMATION CONTACT: Shane Rogers, Designated Federal Official, Division of Medicine and Dentistry, Bureau of Health Workforce, HRSA, 5600 Fishers Lane, Room VerDate Sep<11>2014 18:41 Dec 19, 2022 Jkt 259001 15N142, Rockville, Maryland 20857; 301–443–5260; or SRogers@hrsa.gov. SUPPLEMENTARY INFORMATION: The ACTPCMD provides advice and recommendations to the Secretary of Health and Human Services (Secretary) on policy, program development, and other matters of significance concerning the activities under Section 747 of Title VII of the Public Health Service (PHS) Act, as it existed upon the enactment of Section 749 of the PHS Act in 1998. ACTPCMD prepares an annual report describing the activities of the committee, including findings and recommendations made by the committee concerning the activities under Section 747, as well as training programs in oral health and dentistry. The annual report is submitted to the Secretary as well as the Chair and ranking members of the Senate Committee on Health, Education, Labor and Pensions and the House of Representatives Committee on Energy and Commerce. The ACTPCMD develops, publishes, and implements performance measures and guidelines for longitudinal evaluations of programs authorized under Title VII, Part C of the PHS Act, and recommends appropriation levels for programs under this Part. Since priorities dictate meeting times, be advised that start times, end times, and agenda items are subject to change. For CY 2023 meetings, agenda items may include, but are not limited to, inter-professional team-based education, practice, and retention in underserved rural communities, as well as matters pertaining to policy, program development, and other matters of significance concerning medicine and dentistry activities authorized under the relevant sections of the PHS Act. Refer to the ACTPCMD website listed above for all current and updated information concerning the CY 2023 ACTPCMD meetings, including agendas and meeting materials that will be posted 30 calendar days before the meeting. Members of the public will have the opportunity to provide comments. Public participants may submit written statements in advance of the scheduled meeting(s). Oral comments will be honored in the order they are requested and may be limited as time allows. Requests to submit a written statement or make oral comments to the ACTPCMD should be sent to Shane Rogers using the contact information above at least 5 business days before the meeting date(s). Individuals who need special assistance or another reasonable accommodation should notify Shane Rogers using the contact information PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 listed above at least 10 business days before the meeting(s) they wish to attend. Maria G. Button, Director, Executive Secretariat. [FR Doc. 2022–27541 Filed 12–19–22; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Advisory Commission on Childhood Vaccines Meeting Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS). ACTION: Notice. AGENCY: In accordance with the Federal Advisory Committee Act, this notice announces that the Advisory Commission on Childhood Vaccines (ACCV) will hold public meetings for the 2023 calendar year (CY). Information about the ACCV, agendas, and materials for these meetings can be found on the ACCV website at https:// www.hrsa.gov/advisory-committees/ vaccines/. DATES: The ACCV meetings will be held on: • March 1, 2023, 10:00 a.m. Eastern Time (ET)–4:00 p.m. ET; • March 2, 2023, 10:00 a.m. ET–4:00 p.m. ET; • September 6, 2023, 10:00 a.m. ET– 4:00 p.m. ET; and • September 7, 2023, 10:00 a.m. ET– 4:00 p.m. ET. ADDRESSES: Meetings may be held inperson or by Zoom webinar. For updates on how the meeting will be held, visit the ACCV website 30 business days before the date of the meeting, where instructions for joining meetings either in-person or remotely will be posted. Inperson ACCV meetings will be held at 5600 Fishers Lane, Rockville, Maryland 20857. For meeting information updates, go to the ACCV website meeting page at https://www.hrsa.gov/ advisory-committees/vaccines/ meetings.html. SUMMARY: Pita Gomez, Principal Staff Liaison, Division of Injury Compensation Programs, HRSA, 5600 Fishers Lane, 08N186B, Rockville, Maryland 20857; 301–945– 9386; or ACCV@hrsa.gov. SUPPLEMENTARY INFORMATION: The ACCV provides advice and recommendations to the Secretary of HHS (Secretary) on policy, program development, and other FOR FURTHER INFORMATION CONTACT: E:\FR\FM\20DEN1.SGM 20DEN1 lotter on DSK11XQN23PROD with NOTICES1 Federal Register / Vol. 87, No. 243 / Tuesday, December 20, 2022 / Notices issues related to implementation of the National Vaccine Injury Compensation Program and concerning other matters as described under section 2119 of the Public Health Service Act (42 U.S.C. 300aa–19). Since priorities dictate meeting times, be advised that start times, end times, and agenda items are subject to change. Refer to the ACCV website listed above for any meeting updates that may occur. For CY 2023 meetings, agenda items may include, but are not limited to: updates from the Division of Injury Compensation Programs, Department of Justice, Office of Infectious Disease and HIV/AIDS Policy (HHS), Immunization Safety Office (Centers for Disease Control and Prevention), National Institute of Allergy and Infectious Diseases (National Institutes of Health) and Center for Biologics, Evaluation and Research (Food and Drug Administration). Refer to the ACCV website listed above for all current and updated information concerning the CY 2023 ACCV meetings, including draft agendas and meeting materials that will be posted 5 calendar days before the meeting. These meetings are open to the public. Meetings held by Zoom webinar will require registration. Registration details will be provided on the ACCV website at https://www.hrsa.gov/ advisory-committees/vaccines/ meetings.html. All registrants will be asked to provide their name, affiliation, and email address. After registration, individuals will receive personalized Zoom information via email. Members of the public will have the opportunity to provide comments. Public participants may submit written statements in advance of the scheduled meeting(s). Oral comments will be honored in the order they are requested and may be limited as time allows. Requests to submit a written statement or make oral comments to the ACCV should be sent to Pita Gomez using the contact information above at least 5 business days before the meeting date(s). Individuals who need special assistance or another reasonable accommodation should notify Pita Gomez using the contact information listed above at least 10 business days before the meeting(s) they wish to attend. If an in-person meeting is held, it will occur in a federal government building, and attendees must go through a security check to enter the building. Non-U.S. citizen attendees must notify HRSA of their planned attendance at least 20 business days prior to the meeting in order to facilitate their entry into the building. All attendees are VerDate Sep<11>2014 18:41 Dec 19, 2022 Jkt 259001 required to present government-issued identification prior to entry. Maria G. Button, Director, Executive Secretariat. [FR Doc. 2022–27543 Filed 12–19–22; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Advancing Translational Sciences; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel; CTSA Specialized Innovation Program. Date: February 9, 2023. Time: 11:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1037, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Carol (Chang-Sook) Kim, Ph.D., Scientific Review Administrator, Office of Grants Management and Scientific Review, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1037, Bethesda, MD 20892, (301) 827–7940, carolko@mail.nih.gov. Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel; Rare Disease Review. Date: February 23, 2023. Time: 10:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1037, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Jing Chen, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1037, Bethesda, MD 20892, (301) 827–3268, chenjing@ mail.nih.gov. PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 77853 Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel; CTSA Small Grant Program. Date: February 24, 2023. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1037, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Carol (Chang-Sook) Kim, Ph.D., Scientific Review Administrator, Office of Grants Management and Scientific Review, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1037, Bethesda, MD 20892, (301) 827–7940, carolko@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS) Dated: December 15, 2022. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–27604 Filed 12–19–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY [Docket No. DHS–2022–0037] Homeland Security Advisory Council The Office of Partnership and Engagement (OPE), The Department of Homeland Security (DHS). ACTION: Notice of charter amendment. AGENCY: The Homeland Security Advisory Council has amended its charter. SUMMARY: FOR FURTHER INFORMATION CONTACT: Rebecca F. Sternhell at HSAC@ hq.dhs.gov or at 202–891–2876. SUPPLEMENTARY INFORMATION: The Homeland Security Advisory Council (HSAC) was established in April 2003, under the authority of title 6 United States Code, section 451, and chartered under the provisions of the Federal Advisory Committee Act (FACA), 5 U.S.C. app. This discretionary Council provides nonpartisan and organizationally independent strategic advice to the Secretary of Homeland Security on critical matters related to Homeland Security. The HSAC has made the following three amendments to its charter. 1. The previous charter stated there was one Chair. It is now amended to provide for two co-Chairs and a ViceChair who will support the co-Chairs. E:\FR\FM\20DEN1.SGM 20DEN1

Agencies

[Federal Register Volume 87, Number 243 (Tuesday, December 20, 2022)]
[Notices]
[Pages 77852-77853]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-27543]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration


Advisory Commission on Childhood Vaccines Meeting

AGENCY: Health Resources and Services Administration (HRSA), Department 
of Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Federal Advisory Committee Act, this 
notice announces that the Advisory Commission on Childhood Vaccines 
(ACCV) will hold public meetings for the 2023 calendar year (CY). 
Information about the ACCV, agendas, and materials for these meetings 
can be found on the ACCV website at https://www.hrsa.gov/advisory-committees/vaccines/.

DATES: The ACCV meetings will be held on:
     March 1, 2023, 10:00 a.m. Eastern Time (ET)-4:00 p.m. ET;
     March 2, 2023, 10:00 a.m. ET-4:00 p.m. ET;
     September 6, 2023, 10:00 a.m. ET-4:00 p.m. ET; and
     September 7, 2023, 10:00 a.m. ET-4:00 p.m. ET.

ADDRESSES: Meetings may be held in-person or by Zoom webinar. For 
updates on how the meeting will be held, visit the ACCV website 30 
business days before the date of the meeting, where instructions for 
joining meetings either in-person or remotely will be posted. In-person 
ACCV meetings will be held at 5600 Fishers Lane, Rockville, Maryland 
20857. For meeting information updates, go to the ACCV website meeting 
page at https://www.hrsa.gov/advisory-committees/vaccines/meetings.html.

FOR FURTHER INFORMATION CONTACT: Pita Gomez, Principal Staff Liaison, 
Division of Injury Compensation Programs, HRSA, 5600 Fishers Lane, 
08N186B, Rockville, Maryland 20857; 301-945-9386; or [email protected].

SUPPLEMENTARY INFORMATION: The ACCV provides advice and recommendations 
to the Secretary of HHS (Secretary) on policy, program development, and 
other

[[Page 77853]]

issues related to implementation of the National Vaccine Injury 
Compensation Program and concerning other matters as described under 
section 2119 of the Public Health Service Act (42 U.S.C. 300aa-19).
    Since priorities dictate meeting times, be advised that start 
times, end times, and agenda items are subject to change. Refer to the 
ACCV website listed above for any meeting updates that may occur. For 
CY 2023 meetings, agenda items may include, but are not limited to: 
updates from the Division of Injury Compensation Programs, Department 
of Justice, Office of Infectious Disease and HIV/AIDS Policy (HHS), 
Immunization Safety Office (Centers for Disease Control and 
Prevention), National Institute of Allergy and Infectious Diseases 
(National Institutes of Health) and Center for Biologics, Evaluation 
and Research (Food and Drug Administration). Refer to the ACCV website 
listed above for all current and updated information concerning the CY 
2023 ACCV meetings, including draft agendas and meeting materials that 
will be posted 5 calendar days before the meeting.
    These meetings are open to the public. Meetings held by Zoom 
webinar will require registration. Registration details will be 
provided on the ACCV website at https://www.hrsa.gov/advisory-committees/vaccines/meetings.html. All registrants will be asked to 
provide their name, affiliation, and email address. After registration, 
individuals will receive personalized Zoom information via email.
    Members of the public will have the opportunity to provide 
comments. Public participants may submit written statements in advance 
of the scheduled meeting(s). Oral comments will be honored in the order 
they are requested and may be limited as time allows. Requests to 
submit a written statement or make oral comments to the ACCV should be 
sent to Pita Gomez using the contact information above at least 5 
business days before the meeting date(s).
    Individuals who need special assistance or another reasonable 
accommodation should notify Pita Gomez using the contact information 
listed above at least 10 business days before the meeting(s) they wish 
to attend. If an in-person meeting is held, it will occur in a federal 
government building, and attendees must go through a security check to 
enter the building. Non-U.S. citizen attendees must notify HRSA of 
their planned attendance at least 20 business days prior to the meeting 
in order to facilitate their entry into the building. All attendees are 
required to present government-issued identification prior to entry.

Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2022-27543 Filed 12-19-22; 8:45 am]
BILLING CODE 4165-15-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.